Said Masri

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

David K Howse, A. Verier, M. Valis, 2018, Multiple sclerosis and related disorders.

Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study

W. Camu, Sabine Latour, Said Masri, 2010, Patient preference and adherence.

The natural history of primary progressive multiple sclerosis: insights from the German NeuroTransData registry

R. Fleischer, C. Hofer, H. Peters, 2023, BMC Neurology.